Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Phenobarbital
Drug ID BADD_D01752
Description A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Indications and Usage For the treatment of all types of seizures except absence seizures.
Marketing Status approved; investigational
ATC Code N03AA02
DrugBank ID DB01174
KEGG ID D00506
MeSH ID D010634
PubChem ID 4763
TTD Drug ID D0Y7RW
NDC Product Code 75826-142; 13517-626; 13517-628; 13517-758; 0121-0531; 51293-692; 54932-501; 63629-2399; 69367-214; 70752-163; 71205-892; 16571-673; 0143-1455; 0143-1458; 54932-207; 58118-0626; 60687-448; 62135-406; 62135-412; 63629-1033; 63629-2043; 63629-2045; 63629-2400; 70752-157; 70752-165; 70752-168; 71205-848; 72162-1584; 76003-0894; 13517-691; 16571-671; 0143-1500; 43063-953; 51293-693; 60687-671; 62135-405; 62135-410; 63629-1037; 63629-2402; 69367-172; 70518-2405; 70518-2418; 70518-3469; 70518-3470; 70752-164; 71205-851; 71205-891; 0603-1508; 0603-5165; 58118-1110; 64380-166; 70518-0911; 71205-890; 16571-669; 51293-691; 63629-1034; 63629-1038; 71205-845; 71205-846; 0603-5166; 75826-139; 75826-140; 50095-001; 66064-2001; 13517-625; 13517-627; 13517-693; 13517-757; 16571-672; 51293-627; 63629-2047; 63629-2291; 63629-2403; 70518-3471; 70752-167; 0603-5167; 72162-1583; 75826-143; 0904-6575; 13517-107; 13517-111; 13517-692; 13517-694; 17856-0174; 51293-625; 58118-1626; 62135-409; 63629-1035; 63629-1036; 63629-1039; 63629-2046; 63629-2049; 69367-211; 70518-2407; 70752-162; 13517-110; 13517-756; 16571-667; 16571-668; 16571-670; 0143-1495; 51293-694; 63187-895; 63629-2044; 63629-2289; 63629-2401; 63739-192; 63739-294; 69367-213; 71205-847; 71205-850; 0603-5168; 72162-1581; 75826-136; 75826-137; 51927-1015; 16571-675; 51293-628; 62135-407; 62135-411; 63629-1032; 63629-2041; 63629-2042; 63629-2048; 63629-2290; 69367-212; 70752-166; 71205-849; 71205-889; 71205-893; 72162-1582; 38779-0852; 51552-0745; 58624-0520; 59348-0011; 65319-1450; 62135-408; 63629-2404; 70166-536; 70166-537; 70518-2612; 70752-161; 75826-138; 75826-141; 13517-112; 13517-113; 13517-755; 16571-674; 17856-0678; 51293-626
UNII YQE403BP4D
Synonyms Phenobarbital | Phenylbarbital | Phenylethylbarbituric Acid | Acid, Phenylethylbarbituric | Phenemal | Phenobarbitone | Hysteps | Phenobarbital Sodium | Sodium, Phenobarbital | Phenobarbital, Monosodium Salt | Monosodium Salt Phenobarbital | Luminal | Gardenal
Chemical Information
Molecular Formula C12H12N2O3
CAS Registry Number 50-06-6
SMILES CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Deafness04.02.01.0010.000325%Not Available
Dehydration14.05.05.0010.000325%
Delirium19.13.02.001--
Depressed level of consciousness17.02.04.0020.000325%
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.000488%
Developmental delay19.07.05.003; 08.01.03.037--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Drug ineffective08.06.01.0060.002016%Not Available
Drug interaction08.06.03.0010.001203%Not Available
Dry mouth07.06.01.002--
Emotional disorder19.04.02.005--Not Available
Eosinophilia01.02.04.0010.000488%
Epilepsy17.12.03.0020.000813%Not Available
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Extravasation08.01.03.008--Not Available
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.000325%
Failure to thrive14.03.02.008; 19.07.05.001; 18.04.01.0030.000325%Not Available
Feeling abnormal08.01.09.014--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Folate deficiency14.12.02.006--Not Available
Gait disturbance08.01.02.002; 15.03.05.013; 17.02.05.016--
Hallucination19.10.04.003--
Hangover08.01.09.018--Not Available
Headache17.14.01.001--
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.000325%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene